Investigational drug · Phase 3
RAP-219
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Focal Epilepsy, Epilepsy, Focal Seizure.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
3 still active
All registered trials
6
Any phase or sponsor naming "RAP-219"
First trial start
2024
Oct 10, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RAP-219", any sponsor or status.
Conditions studied
As listed on its trial records.
- Focal Epilepsy
- Epilepsy
- Focal Seizure
- Refractory Focal Epilepsy
- Seizure
- Focal Onset Seizure
- Bipolar 1 Disorder
- Focal Onset Seizures
Approved drugs for the same conditions: Epilepsy and seizures · Bipolar disorder · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "RAP-219" as an intervention, largest first.
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1Pivotal-lookingRecruiting
Rapport Therapeutics Inc.Industry
NCT07563881 · 333 participants (planned) · Start Jun 5, 2026 · Primary completion Jul 2029
Drug: RAP-219; RAP-219 · For: Focal Seizure; Epilepsy; Focal Epilepsy
Sites: Birmingham, Alabama; Palmdale, California; San Francisco, California · 24 sites in all
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresPivotal-lookingRecruiting
Rapport Therapeutics Inc.Industry
NCT07594119 · 312 participants (planned) · Start Sep 1, 2026 · Primary completion Jul 2029
Drug: RAP-219; RAP-219 · For: Focal Seizure; Epilepsy; Focal Epilepsy
Sites: Huntsville, Alabama; Bentonville, Arkansas; Colorado Springs, Colorado · 14 sites in all
- Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I DisorderPivotal-lookingCompleted
Rapport Therapeutics Inc.Industry
NCT07046494 · 253 participants · Start Jul 25, 2025 · Primary completion Aug 5, 2026
Drug: RAP-219 · For: Bipolar 1 Disorder
Sites: Little Rock, Arkansas; Rogers, Arkansas; Chino, California · 20 sites in all
Rapport Therapeutics Inc.Industry
NCT07923097 · 60 participants (planned) · Start Nov 2026 · Primary completion Jun 2027
Drug: RAP-219 or Placebo · For: Epilepsy
Sites: Adelaide, Australia
Rapport Therapeutics Inc.Industry
NCT06377930 · 30 participants · Start Oct 10, 2024 · Primary completion Sep 26, 2025
Drug: RAP-219 · For: Focal Onset Seizures
Sites: New Haven, Connecticut; Boise, Idaho; Indianapolis, Indiana · 12 sites in all
- A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresRecruiting
Rapport Therapeutics Inc.Industry
NCT07219407 · 30 participants (planned) · Start Dec 15, 2025 · Primary completion Feb 3, 2028
Drug: RAP-219 · For: Focal Epilepsy; Epilepsy; Refractory Focal Epilepsy and 3 more
Sites: Boise, Idaho; Rochester, Minnesota; New York, New York · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Selective γ8 transmembrane α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor regulatory protein negative allosteric modulators: Efficacy in preclinical antiseizure models.
Matta JA, Shireman BT, Volak LP, et al. · Epilepsia 2026
- Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development.
Bialer M, Johannessen Landmark C, Koepp MJ, et al. · Epilepsia 2026
- Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development.
Bialer M, Johannessen SI, Koepp MJ, et al. · Epilepsia 2024
Also in development for Focal Epilepsy
- AzetukalnerXEN1101Phase 39 trials
Xenon Pharmaceuticals Inc. · Focal Onset Seizures, Major Depressive Disorder, Bipolar Disorder
- BHV-7000Phase 36 trials
Biohaven Therapeutics Ltd. · Focal Epilepsy, Major Depressive Disorder, Bipolar Disorder
- Test drug CB03-154 groupPhase 32 trials
Shanghai Zhimeng Biopharma, Inc. · ALS (Amyotrophic Lateral Sclerosis), Focal Epilepsy
- CB03-154Phase 21 trial
Shanghai Zhimeng Biopharma, Inc. · Focal Epilepsy
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.